User:Mr. Ibrahem/Dacomitinib

Dacomitinib, sold under the brand name Vizimpro, is a medication used to treat non-small-cell lung carcinoma (NSCLC). Specifically it is used for cases with certain epidermal growth factor receptor (EGFR) mutations. It is taken by mouth.

Common side effects include diarrhea, rash, mouth inflammation, conjunctivitis, itching, liver problems, and nausea. Other side effects may include interstitial lung disease. Use in pregnancy may harm the baby. It is a tyrosine kinase inhibitor of EGFR.

Dacomitinib was approved for medical use in the United States in 2018 and Europe in 2019. In the United States it costs about 14,300 USD per month as of 2021. This amount in the United Kingdom costs the NHS about £2,700.